Find latest Myeloma videos · 200+ videos
ecancer
L

ASCO® 2024 Insights: "CARTITUDE-4 Study - Benefits of Ciltacabtagene Autoleucel in Lenalidomide-Refractory Functional High-Risk MM"

By ecancer FEATURING Luciano Costa
By ecancer FEATURING Luciano Costa
110 views
June 24, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Related Videos

Penn Medicine Abramson Cancer Center

2025 Breast Cancer Highlights from International Medical Meetings: 5…

Thu, Mar 6, 2025
Total Health

West Oncology Conference

Sat, Feb 8, 2025
15:35

Multiple Myeloma: Not as Simple as "CRAB" Anymore

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Banerjee

535 views
26:59

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

186 views
17:52

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

1.2K views
14:01

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

474 views
24:35

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstr…

2024 ASCO® Annual Meeting Insights Hub

H. Hashmi

629 views
35:27

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

657 views
09:07

CARTITUDE-4 Update: OS With Cilta-Cel vs. SOC in Len-Refractory Mult…

Maria-Victoria Mateos

220 views
21:41

Multiple Myeloma: Hot Topics in 2024

Yale Cancer Center

S. Browning

197 views
16:55

Anti-BMCA Bispecific Antibodies - Independent Symposium at the 10th …

Springer Healthcare IME

S. Usmani

188 views
20:23

When to Consider Bispecific and CAR-T Therapy in MM

SOHO Brazil 2024

N. S. Raje

412 views
45:27

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

302 views
22:33

Treatment Strategies for R/R MM After Frontline Anti-CD38 Therapy

Integrity CE

S. Usmani, J. Hillengass

229 views
24:23

Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?

MyCancerHaven

R. Vij, S. Al Hadidi

626 views
36:10

Highlights in Plasma Cell Disorders From ASCO® and EHA

Insights from 2024 EHA Annual Meeting

S. Al Hadidi

480 views
10:57

New

Indefinite Treatment of Multiple Myeloma: Strategies for Frail Patie…

Shaji Kumar

93 views
12:49

The Relapsed and Refractory MM Patient: When Immune Approaches Are I…

Joseph Mikhael

102 views
13:47

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maintenanc…

2024 ASCO® Annual Meeting Insights Hub

B. Derman

401 views
24:44

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

922 views
16:42

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

H. Hashmi

1.6K views
17:22

Highlights of Recent Updates in Myeloma: Part 2 - R/R Treatment

2024 ASCO® Annual Meeting Insights Hub

A. Jakubowiak

261 views
AUTOPLAY